Glucagon-like peptide-1 (GLP-1) receptor agonists were investigated in 43 (72.9%) studies (Figure 4), with liraglutide being the agent used in 54.2% of all studies
They may drink less, stop before finishing a drink, or feel less interested in the reward of alcohol
One challenge to elucidating a mechanistic role for GLP-1Rs stems from their complex expression across multiple brain regions (1012), including the lateral septal nucleus (LSc), substantia nigra, ventral tegmental area (VTA), amygdala, nucleus accumbens (ACB), hippocampus, several regions of the hypothalamus (paraventricular nucleus of the hypothalamus [PVH], arcuate nucleus [ARH]), and hindbrain
Efficacy of glucagon-like peptide-1 mimetics for neural regeneration
Your doctor may also want to know about any other health conditions you may have, such as diabetes or obesity, that were initially treated with Semaglutide
The main mechanism of cardioprotective effects of GLP-1R agonists against oxidative stress-induced injury in H9c2 cells (cardiomyoblasts from Rattus norvegicus) and in cardiomyocytes is related to the scavenging of reactive oxygen species, by increasing the concentrations of endogenous antioxidant defenses and inhibiting cardiomyocyte apoptosis [42]
